This Week in Medical Journals: March 2026 Highlights

Note: The papers below are illustrative examples to demonstrate the format of our weekly roundup. For real weekly digests tailored to your specialty, start your free trial.

If you're keeping up with the major journals—The Lancet, BMJ, NEJM, JAMA—while juggling a full clinic, you're probably falling behind. This week has brought some noteworthy findings across cardiovascular medicine, primary care, oncology, and mental health that are worth your attention. Here's what you need to know.

Cardiovascular

Intensive Blood Pressure Targets in the Elderly: A Pragmatic RCT

The Lancet | 27 March 2026

A multicentre UK trial compared intensive BP control (target <130 mmHg) versus standard targets (<140 mmHg) in 8,400 adults over 75 with hypertension and existing cardiovascular disease. Surprisingly, the intensive group showed no reduction in major adverse events over 3 years, but did experience higher rates of hypotensive symptoms and falls. The finding challenges current guideline recommendations and may shift practice in frail elderly populations, particularly those with polypharmacy concerns.

Atrial Fibrillation Screening in Primary Care: Cost-Effectiveness Update

The Lancet | 24 March 2026

Researchers used handheld ECG devices in general practice to screen asymptomatic patients aged 65–75 for paroxysmal AF. The study of 12,000 participants found that opportunistic screening identified 2.5% previously undiagnosed AF and prevented one stroke per 40 patients identified over 5 years. The cost per stroke prevented was £28,000, placing it comfortably within NICE threshold and supporting adoption in primary care.

Primary Care

Empirical Antibiotic Choice in Uncomplicated UTIs: Non-Inferiority in Primary Care

BMJ | 25 March 2026

A pragmatic open-label trial randomised 3,800 women in UK general practices with uncomplicated UTI to either standard nitrofurantoin or a 3-day course of amoxicillin-clavulanate. Symptom resolution rates were equivalent (89% vs 87%), and resistance patterns in community samples remained stable. The findings suggest that cost and simplicity might reasonably guide first-line choice in primary care, easing antibiotic stewardship without sacrificing efficacy.

Oncology

PD-L1-Independent Response to Anti-CTLA-4 + Anti-PD-1 in Advanced Melanoma

The New England Journal of Medicine | 20 March 2026

A phase III trial in 1,200 patients with advanced melanoma compared dual checkpoint inhibition (ipilimumab + nivolumab) against nivolumab monotherapy, stratified by PD-L1 expression. Combination therapy improved 2-year OS by 12 percentage points even in the PD-L1–negative group, suggesting that immunotherapy benefit transcends traditional biomarker predictions. This may reshape sequencing decisions in patients deemed "immunotherapy resistant" by conventional criteria.

Mental Health

Flexible SSRI Dosing vs Fixed Dose in Generalised Anxiety: 52-Week Outcomes

JAMA Psychiatry | 28 March 2026

A randomised, double-blind trial of 1,500 adults with GAD assigned patients to flexible sertraline dosing (50–150 mg based on symptom response and tolerability) or fixed 100 mg daily. Flexible dosing showed non-inferior anxiety symptom improvement (GAD-7 reduction of 10 points vs 9.5 points) but with 18% fewer side effects and better medication adherence. The approach aligns clinical practice with evidence and may improve real-world outcomes in primary care mental health.

Endocrinology

Sodium-Glucose Cotransporter-2 Inhibitors in Prediabetes: The PREVENT-DM Study

Lancet Diabetes & Endocrinology | 22 March 2026

A 2-year, double-blind RCT of 4,000 patients with prediabetes and BMI ≥27 kg/m² compared dapagliflozin versus placebo, alongside standard lifestyle counselling. The SGLT2i group showed a 35% relative risk reduction in progression to type 2 diabetes and modest reductions in weight and blood pressure. Interestingly, benefits were seen regardless of baseline HbA1c level, potentially expanding the indication for early intervention in at-risk populations.

Paediatrics

Antibiotic Resistance Patterns in Childhood UTIs: A 5-Year Surveillance Study

Archives of Disease in Childhood | 26 March 2026

Researchers analysed bacterial susceptibility data from 45,000 paediatric UTI urine cultures across 120 UK hospitals from 2021 to 2026. Trimethoprim resistance increased to 38% (from 28% in 2021), whilst nitrofurantoin remained below 5% resistant. The data supports moving away from trimethoprim as empirical first-line therapy in children, with implications for NICE guidance update expected in Q2 2026.

What to Read in Full

If you have time to dig deeper, these three papers warrant close reading:

1. Intensive Blood Pressure Targets in the Elderly (The Lancet) — If you manage elderly patients with hypertension, the original paper details subgroup analyses that may inform individualised target-setting. The safety data on hypotensive symptoms is clinically valuable.

2. PD-L1-Independent Response in Advanced Melanoma (NEJM) — Oncologists and general physicians referring for immunotherapy will find the mechanistic discussion enlightening, and the companion editorial contextualises the implications for first-line versus sequential strategies.

3. SGLT2i in Prediabetes (Lancet Diabetes & Endocrinology) — With increasing pressure to intervene earlier in the metabolic disease continuum, this study provides robust evidence for risk-benefit discussions with patients at high risk of progression.

Every week, thousands of papers land in major journals. Staying current isn't optional—it's foundational to good practice. That's why MCB exists: to distil the signal from the noise and deliver it straight to your inbox, every Monday morning, tailored to your specialty and your schedule. If this week's roundup has been useful, why not explore our guide to keeping up with medical journals or discover why reading too many medical journals is a productivity trap—and how we solve it.

Ready to get summaries like these delivered every week? Start your free trial today.